| Literature DB >> 26979972 |
Keiko Miyamoto1, Miho Iwakuma2, Takeo Nakayama3.
Abstract
BACKGROUND: Because of the rapid development in genomics, more research findings have emerged. However, the association between society and research results remains controversial. This article examines the experiences and attitudes of residents regarding a community-based genomic cohort study.Entities:
Keywords: Drug susceptibility; Familiarity; Genome study; Japan; Public attitude
Mesh:
Year: 2016 PMID: 26979972 PMCID: PMC4793744 DOI: 10.1186/s12920-016-0175-8
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Demographic awareness of the Nagahama study, self-rate understanding of terminology, and willingness toward drug susceptibility genetic testing
| Male ( | Female ( | |||
|---|---|---|---|---|
| % | n | % | n | |
| Age group (years) | ||||
| 30–39 | 16.1 | 112 | 20.7 | 159 |
| 40–49 | 20.1 | 140 | 22.8 | 175 |
| 50–59 | 23.8 | 166 | 26.3 | 202 |
| 60–69 | 40.0 | 279 | 30.2 | 232 |
| Formal educational period | ||||
| High school graduate and lower | 59.1 | 392 | 56.3 | 414 |
| College and higher | 40.9 | 271 | 43.8 | 322 |
| Awareness of the Nagahama study contents | ||||
| Know more than one content | 30.6 | 210 | 50.3 | 381 |
| Know nothing | 69.7 | 483 | 49.7 | 376 |
| Self-rated understanding of terminology | ||||
| Higha | 35.7 | 251 | 24.1 | 185 |
| Mediumb | 35.1 | 247 | 35.0 | 269 |
| Lowc | 28.0 | 197 | 38.4 | 295 |
| Willingness toward drug susceptibility genetic testing (Would you like to donate your DNA for drug susceptibility genetic testing?) | ||||
| Yes | 49.3 | 339 | 47.9 | 360 |
| Neutral | 27.2 | 187 | 32.0 | 240 |
| No | 23.4 | 161 | 20.1 | 151 |
aUnderstanding “gene” and “genome” and understanding “gene” and having heard of “genome”
bHaving heard of “gene” and “genome” or understanding “gene” and having never known about “genome”
cHaving of “gene” and not “genome” or having never known about “gene” nor “genome”
Differences in individual factors between those who were aware of the Nagahama study and those who knew nothing about the Nagahama study from Qui-square test
| Male ( | Female ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Aware of the Nagahama study ( | Know nothing ( | OR | 95 % CI |
| Aware of the Nagahama study ( | Know nothing ( | OR | 95 % CI |
| |
| Age group years) | ||||||||||
| 30–39 | 25.2 | 74.8 | 1 | 40.3 | 59.7 | 1 | ||||
| 40–49 | 20.9 | 79.1 | 0.78 | 0.43–1.41 | 0.415 | 43.7 | 56.3 | 1.15 | 0.74–1.78 | 0.527 |
| 50–59 | 26.8 | 73.2 | 1.09 | 0.63–1.88 | 0.767 | 57.9 | 42.1 | 2.04 | 1.33–3.12 | 0.001 |
| 60–69 | 38.6 | 61.4 | 1.86 | 1.14–3.05 | 0.013 | 55.9 | 44.1 | 1.89 | 1.25–2.84 | 0.003 |
| Formal education period | ||||||||||
| High school graduate and | 30.4 | 69.6 | 1 | 47.9 | 52.1 | 1 | ||||
| College and higher | 31.1 | 68.9 | 0.97 | 0.69–1.35 | 0.844 | 53.9 | 46.1 | 0.79 | 0.59–1.06 | 0.109 |
| Self-rated understanding of terminology | ||||||||||
| High | 37.3 | 62.7 | 1 | 62.8 | 37.2 | 1 | ||||
| Middle | 30.7 | 69.3 | 0.74 | 0.51–1.08 | 0.122 | 51.5 | 48.5 | 0.63 | 0.43–0.92 | 0.018 |
| Low | 21.1 | 78.9 | 0.45 | 0.29–0.69 | <0.001 | 41.6 | 58.4 | 0.42 | 0.29–0.62 | <0.001 |
| Awareness of benefits | ||||||||||
| Helpful for disease diagnosis | 91.1 | 79.0 | 2.73 | 1.60–4.66 | <0.001 | 90.2 | 77.0 | 2.76 | 1.80–4.23 | <0.001 |
| Helpful for disease treatment | 93.2 | 78.3 | 3.77 | 2.10–6.78 | <0.001 | 89.1 | 76.5 | 2.51 | 1.66–3.79 | <0.001 |
| Helpful for disease prevention | 90.2 | 75.7 | 2.96 | 1.78–4.92 | <0.001 | 89.1 | 77.0 | 2.44 | 1.61–3.70 | <0.001 |
| Concerns | ||||||||||
| Financial infusion | 79.7 | 77.7 | 1.13 | 0.75–1.69 | 0.572 | 78.7 | 74.4 | 1.27 | 0.90–1.80 | 0.180 |
| Privacy concerns | 57.7 | 61.7 | 0.85 | 0.61–1.19 | 0.339 | 56.3 | 52.8 | 1.15 | 0.86–1.55 | 0.355 |
| Discriminations | 40.4 | 45.0 | 0.83 | 0.59–1.16 | 0.275 | 38.5 | 37.2 | 1.06 | 0.78–1.44 | 0.711 |
| Unexpected negative effects | 34.0 | 42.8 | 0.68 | 0.49–0.97 | 0.034 | 30.5 | 32.6 | 0.91 | 0.66–1.25 | 0.564 |
| Cloned human beings | 33.5 | 37.0 | 0.86 | 0.61–1.22 | 0.387 | 29.0 | 32.0 | 0.87 | 0.63–1.20 | 0.391 |
| Belief | ||||||||||
| Company or government bodies use genome information | 44.5 | 45.6 | 0.96 | 0.69–1.34 | 0.796 | 39.9 | 38.8 | 1.05 | 0.78–1.42 | 0.758 |
Fig 1Attitudes toward the use of genetic information for medical purposes
Relationship between awareness of the benefit of genome study and awareness of the Nagahama study, self-rated understanding of terminology, concern, and belief of usage of genetic information in companies or government bodies from Logistic Regression Analysis
| Male ( | Female ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| The use of genetic information is helpful for disease treatment | The use of genetic information is helpful for disease treatment | |||||||||
| Agree ( | Neutral or Disagree | ORa | 95 % CI |
| Agree ( | Neutral or Disagree | ORa | 95 % CI |
| |
| n (%) | n (%) | n (%) | n (%) | |||||||
| High awareness of the Nagahama study | 191 (34.8) | 14 (12.4) | 3.82 | 1.93–7.57 | 326 (55.6) | 40 (33.3) | 2.63 | 1.63–4.24 | <0.001 | |
| Self-rated understanding of terminology | ||||||||||
| High | 231 (41.8) | 19 (16.5) | 1 | 168 (28.8) | 15 (12.6) | 1 | ||||
| Middle | 206 (37.3) | 30 (26.1) | 0.66 | 0.34–1.29 | 0.223 | 224 (38.4) | 37 (31.1) | 0.72 | 0.36–1.42 | 0.342 |
| Low | 116 (21.0) | 66 (57.4) | 0.24 | 0.12–0.46 | <0.001 | 192 (32.9) | 67 (56.3) | 0.49 | 0.27–0.98 | 0.045 |
| Concerns | ||||||||||
| Financial infusion | 456 (84.0) | 60 (52.2) | 4.37 | 2.49–7.69 | <0.001 | 473 (81.4) | 65 (53.7) | 2.98 | 1.79–4.97 | <0.001 |
| Privacy concerns | 343 (62.5) | 56 (49.6) | 0.72 | 0.39–1.32 | 0.284 | 335 (56.9) | 53 (43.8) | 1.00 | 0.57–1.74 | 0.993 |
| Discriminations | 250 (45.3) | 39 (34.2) | 1.38 | 0.74–2.58 | 0.315 | 234 (39.9) | 38 (31.4) | 0.77 | 0.43–1.38 | 0.386 |
| Unexpected negative effects | 228 (41.4) | 38 (33.0) | 1.02 | 0.54–1.93 | 0.963 | 192 (32.6) | 33 (27.5) | 0.49 | 0.26–0.90 | 0.022 |
| Cloned human beings | 203 (37.0) | 35 (30.4) | 0.87 | 0.46–1.66 | 0.682 | 191 (32.5) | 24 (20.2) | 2.27 | 1.16–4.46 | 0.017 |
| Belief | ||||||||||
| Company or government bodies use genome information | 267 (48.8) | 33 (29.7) | 1.35 | 0.77–2.36 | 0.299 | 251 (42.7) | 30 (25.0) | 1.71 | 0.98–3.00 | 0.060 |
Adjusted according to age and formal education duration
Relationship between the willingness toward drug susceptibility genetic studies and the attitudes toward genome studies from Logistic Regression Analysis
| Male ( | Female ( | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Willingness toward drug susceptibility genetic studies | Willingness toward drug susceptibility genetic studies | |||||||||
| Yes ( | Neutral or No ( | ORa | 95 % CI |
| Yes ( | Neutral or No ( | ORa | 95 % CI |
| |
| n (%) | n (%) | n (%) | n (%) | |||||||
| High awareness of the Nagahama study | 131 (38.9) | 77 (22.5) | 2.06 | 1.40–3.03 | <0.001 | 200 (56.0) | 178 (46.4) | 1.28 | 0.92–1.79 | 0.150 |
| Self-rated understanding of terminology | ||||||||||
| High | 162 (47.9) | 88 (25.3) | 1 | 117 (32.8) | 67 (17.5) | 1 | ||||
| Middle | 120 (35.5) | 124 (35.6) | 0.58 | 0.39–0.87 | 0.008 | 148 (41.5) | 119 (31.2) | 0.81 | 0.53–1.22 | 0.307 |
| Low | 56 (16.6) | 136 (39.1) | 0.33 | 0.20–0.54 | <0.001 | 92 (25.8) | 196 (51.3) | 0.35 | 0.22–0.55 | <0.001 |
| The use of genetic information is helpful for disease treatment | 311 (94.0) | 241 (71.9) | 3.41 | 1.93–6.01 | <0.001 | 317 (90.1) | 272 (76.0) | 2.51 | 1.54–4.07 | <0.001 |
| Concerns | ||||||||||
| Financial infusion | 268 (82.5) | 247 (74.6) | 0.98 | 0.60–1.60 | 0.941 | 280 (80.2) | 260 (73.2) | 0.90 | 0.59–1.38 | 0.629 |
| Privacy concerns | 199 (60.9) | 197 (59.3) | 0.93 | 0.59–1.45 | 0.739 | 200 (56.7) | 190 (52.9) | 0.94 | 0.63–1.40 | 0.762 |
| Discriminations | 139 (42.0) | 147 (44.3) | 0.83 | 0.53–1.28 | 0.289 | 145 (41.2) | 127 (35.7) | 1.17 | 0.78–1.75 | 0.459 |
| Unexpected negative effects | 131 (39.7) | 133 (39.9) | 1.09 | 0.70–1.70 | 0.696 | 117(33.1) | 112 (31.1) | 0.97 | 0.63–1.49 | 0.891 |
| Cloned human beings | 114 (34.5) | 122 (36.9) | 0.85 | 0.54–1.34 | 0.934 | 143 (40.7) | 137 (38.3) | 1.04 | 0.67–1.61 | 0.872 |
| Belief | ||||||||||
| Company or government | 161 (49.4) | 137 (41.4) | 1.32 | 0.89–1.94 | 0.167 | 143 (40.7) | 137 (38.3) | 0.89 | 0.61–1.29 | 0.529 |
Adjusted according to age and formal education duration